文献速递类风湿关节炎

洛伐他汀治疗轻度活动性类风湿关节炎的双盲安慰剂对照II期随机研究

A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

本研究为12周随机双盲安慰剂对照试验,纳入64例临床轻度活动但CRP升高的RA患者,评估洛伐他汀对平均log CRP的影响。结果显示两组平均log CRP下降无显著差异,疾病活动度及生物标志物均无显著变化;事后分析中未使用生物制剂者洛伐他汀组CRP下降≥20%的比例显著高于安慰剂组(P=0.007)。洛伐他汀耐受良好,无严重安全性问题。

要点

  • 洛伐他汀12周治疗未显著降低RA患者平均log CRP或改善疾病活动度。
  • 未使用生物制剂者中洛伐他汀组CRP下降≥20%的比例显著高于安慰剂组(P=0.007)。
  • 洛伐他汀耐受良好,无严重安全性问题。

核心结论

  • 洛伐他汀治疗12周对RA疾病活动度无抗炎或临床效果。
  • 洛伐他汀对未使用生物制剂者的CRP有适度影响,提示他汀可能在特定患者中具有抗炎作用。

研究设计与样本

  • 随机双盲安慰剂对照12周试验,纳入64例临床轻度活动但CRP升高的RA患者。
  • 主要疗效终点为平均log CRP下降,次要终点包括疾病活动度、RF和抗CCP抗体滴度,机制终点包括血清细胞因子水平。

主要发现

  • 两组平均log CRP下降无显著差异,两治疗组疾病活动度均无变化。
  • 机制分析未显示任何生物标志物显著变化。
  • 事后分析中未使用生物制剂者洛伐他汀组CRP下降≥20%的比例显著高于安慰剂组(P=0.007),使用生物制剂者无差异。
  • 洛伐他汀耐受良好,无严重安全性问题。

关键数值与推荐

  • 主要疗效终点为平均log CRP下降。
  • 事后分析中未使用生物制剂者洛伐他汀组CRP下降≥20%的比例显著高于安慰剂组(P=0.007)。

临床怎么用

  • 不推荐使用洛伐他汀治疗RA疾病活动度。
  • 对未使用生物制剂的RA患者,他汀可能具有适度抗炎作用,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: 3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors (statins) are standard treatment for hyperlipidaemia. In addition to lipid-lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of this study were to determine whether treatment of patients with RA with lovastatin decreased CRP or reduced disease activity. METHODS: We conducted a randomized double-blind placebo-controlled 12 week trial of lovastatin vs placebo in 64 RA patients with mild clinical disease activity but an elevated CRP. The primary efficacy end point was the reduction in mean log CRP. Secondary end points included disease activity, RF and anti-CCP antibody titres. Mechanistic end points included levels of serum cytokines. Safety was assessed; hepatic and muscle toxicities were of particular interest. RESULTS: Baseline features were similar between groups. No significant difference in mean log CRP reduction between the two groups was observed, and disease activity did not change from baseline in either treatment group. Mechanistic analyses did not reveal significant changes in any biomarkers. A post hoc analysis of subjects not using biologic therapy demonstrated a significantly greater proportion achieving ⩾20% reduction in CRP from baseline in the lovastatin group compared with placebo (P-value = 0.007). No difference was observed in subjects receiving biologics. Lovastatin was well tolerated with no serious safety concerns. CONCLUSION: This study showed no anti-inflammatory or clinical effects on RA disease activity after 12 weeks of treatment with lovastatin. Lovastatin had a modest effect on CRP in subjects not using biologics, suggesting statins may be anti-inflammatory in selected patients. TRIAL REGISTRATION: ClinicalTrials.gov, http://clinicaltrials.gov, NCT00302952.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Aranow C, Cush J, Bolster MB, et al. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 31628482. doi:10.1093/rheumatology/kez471

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。